September 8th, 2010
(AHOM.OB) ;American HomePatient, Inc. Extends Self-Tender Offer For All Outstanding Shares Of Common Stock
Posted on 30. Aug, 2010 by PublicWire
(PublicWire.com Medical News Release) American HomePatient, Inc. (OTCBB: AHOM) (”American HomePatient” or the “Company”), one of the nation’s largest home health care providers, today announced that it is extending its previously announced self-tender offer for all outstanding shares of common stock of the Company at $0.67 per share, until 5:00 P.M., New York City time, Wednesday, September 1, 2010, unless the tender offer is further extended. The tender offer was previously set to expire at 5:00 P.M., New York City Time, Wednesday, August 25, 2010.
Furthermore, American HomePatient (with the consent of Highland Capital Management, L.P. (”Highland”)) is modifying the tender offer condition that the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 90% of the then outstanding shares of common stock (the “Minimum Condition”). Instead of 90%, the Minimum Condition will now be satisfied if the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 80% of the then outstanding shares of common stock.
As of the close of business on August 25, 2010, 6,896,041 shares of common stock had been tendered in and not withdrawn from the offer. These tendered shares, when added to the number of shares owned by Highland and its affiliates, constitute approximately 87% of the outstanding shares of common stock.
(AHOM.OB) ;American HomePatient, Inc. Extends Self-Tender Offer For All Outstanding Shares Of Common Stock
AHOM.OB, AHOM.OTCBB, OTCBB:AHOM, AHOM
Forward Looking Statements
Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “potential,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the “company to be materially different from those expressed or implied by such forward-looking statements.
For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us, toll free, at 888-843-1412.
(PublicWire.com Medical News Release) American HomePatient, Inc. (OTCBB: AHOM) (”American HomePatient” or the “Company”), one of the nation’s largest home health care providers, today announced that it is extending its previously announced self-tender offer for all outstanding shares of common stock of the Company at $0.67 per share, until 5:00 P.M., New York City time, Wednesday, September 1, 2010, unless the tender offer is further extended. The tender offer was previously set to expire at 5:00 P.M., New York City Time, Wednesday, August 25, 2010.
Furthermore, American HomePatient (with the consent of Highland Capital Management, L.P. (”Highland”)) is modifying the tender offer condition that the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 90% of the then outstanding shares of common stock (the “Minimum Condition”). Instead of 90%, the Minimum Condition will now be satisfied if the number of shares tendered, when added to the number of shares owned by Highland and its affiliates, constitutes at least 80% of the then outstanding shares of common stock.
As of the close of business on August 25, 2010, 6,896,041 shares of common stock had been tendered in and not withdrawn from the offer. These tendered shares, when added to the number of shares owned by Highland and its affiliates, constitute approximately 87% of the outstanding shares of common stock.
(AHOM.OB) ;American HomePatient, Inc. Extends Self-Tender Offer For All Outstanding Shares Of Common Stock
AHOM.OB, AHOM.OTCBB, OTCBB:AHOM, AHOM
Forward Looking Statements
Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate, “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “potential,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the “company to be materially different from those expressed or implied by such forward-looking statements.
For all the latest in small cap news, videos, and information, visit us online at PublicWire.com, or call us, toll free, at 888-843-1412.
SinoFresh Nasal Spray (SFSH.PK) Achieves Positive Results Against H1N1 (Swine Flu) Virus in Initial Pilot Animal Study
Posted on 24. Nov, 2009 by PublicWire in Medical
24 November 2009 (PublicWire) — SinoFresh HealthCare, Inc. (PINKSHEETS: SFSH) announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 (”swine flu”) virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.
Dr. Michael Stampar, D.O., Senior Medical Advisor to SinoFresh HealthCare Products, stated, “We are very encouraged by this initial study report and will continue to develop data to support our belief that SinoFresh Nasal Spray, a broad-based antiseptic solution, is an important component in protecting the health of patients that are exposed to the H1N1 (’swine flu’) virus.”
The study, which was conducted by SRS International Corp. of Falls Church, VA, was conducted over 14 days and was designed to evaluate the severity of infection from H1N1 (”swine flu”) virus in the Cotton Rat animal model, a well accepted model for studying human nasal and respiratory tract infection by viruses and other microbial pathogens. In this study, the test animals were inoculated with H1N1 and then received SinoFresh Nasal Spray in the nose three times daily for 14 days.
The study evaluated the product’s likelihood of efficacy in both prevention and treatment. One group of animals was treated with SinoFresh Nasal Spray prior to inoculation with H1N1 and a second group was treated starting 15 minutes after inoculation with H1N1 while the remaining “control group” received no treatment during the overall 14-day study period.
The Company has now also initiated a study to evaluate the product’s ability to reduce or eliminate viral shedding which is the main method of transmission of the H1N1 flu virus. The active phase of the additional study has been completed and is in the laboratory for evaluation. Results are expected in the next few weeks.
About SinoFresh(TM) HealthCare, Inc.
SinoFresh(TM) HealthCare, Inc. is a developer and marketer of therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms suspected of causing pathogenesis of the mouth nose and throat. The Company holds certain patents and patent applications on its innovative pharmaceutical technology and relies upon a panel of medical experts and management team experienced in the bio-pharmaceutical industry.
The Company’s product, SinoFresh(TM) Nasal & Sinus Care, is the only over-the-counter antiseptic nasal spray that kills bacteria and fungi and viral pathogens in the throat and nasal passages. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that affects many Americans annually. More information is available at www.sinofresh.com.
*SinoFresh(TM) is a trademark of SinoFresh HealthCare, Inc.
For further information company can be contacted at 888-460-4774, or on the web at www.sinofreshproducts.com, or by email at customerservice@sinofreshproducts.com.
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company’s filings with the Securities and Exchange commission, including risks summarized in the company’s annual Report of form 10-KSB for its fiscal year ended December 31, 2006 (file No.49764). The Company’s actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.
Contact:
SinoFresh
888-460-4774
www.sinofreshproducts.com
customerservice@sinofreshproducts.com
InfuSystem Holdings (INHI.OB) to Present at Lazard Capital Markets Healthcare Conference
Posted on 12. Nov, 2009 by PublicWire in Medical
12 November 2009 (Public Wire) –InfuSystem Holdings, Inc. (OTCBB: INHI); (OTCBB: INHIW); (OTCBB: INHIU), the leading provider of ambulatory infusion pumps and associated clinical services, today announced that it will participate in Lazard Capital Markets 6th Annual Healthcare Conference, to be held November 17-18, 2009, in New York. Sean McDevitt, Chairman and Chief Executive Officer of InfuSystem, is scheduled to present on Wednesday, November 18, at 1:45 PM Eastern time at the conference.
About InfuSystem Holdings, Inc.
InfuSystem is the leading supplier of infusion services to oncologists and other outpatient treatment settings. The Company provides pole mounted and ambulatory pumps, supplies and related clinical, biomedical and billing services to practices and patients, nationwide. The Company’s unique suite of services appeals to practices, patients and payors by improving access to clinically necessary medical equipment, while driving down costs and maximizing clinical outcomes.
CONTACT:
Asher Dewhurst
Bob East
Westwicke Partners
(443) 213-0500
HemaCare Reports Eighth Consecutive Profitable Quarter
Posted on 09. Nov, 2009 by PublicWire in Medical
9 November 2009 (PublicWire) — HemaCare Corporation (OTCBB: HEMA) announced today third quarter 2009 results, which include a 168% increase in income from operations compared to the same quarter of 2008. Income from operations was $158,000 versus $59,000 for the third quarter of 2008, and $659,000 on a year-to-date basis, compared to $422,000 in 2008. Net income in the quarter was $233,000, or $0.02 per share, compared to $285,000, or $0.03 per share, in the third quarter of 2008; however, the prior year period included a non-recurring gain of $396,000 related to litigation settlement.
Gross profit from continuing operations decreased $58,000, or 4%, in the quarter to $1.5 million, primarily driven by an 11% decrease in revenue compared to prior year, attributable to a 17% decrease in blood products revenue. This was the result of increased competition caused by an unprecedented excess supply of blood products in the United States due to the recent downturn in the economy. Gross profit margin from continuing operations in the quarter was 17%, compared to 16% in the third quarter of 2008.
Commenting on the results, John Doumitt, the Company’s Chief Executive Officer, stated, “While this was a challenging revenue quarter for the Company, we are pleased to have maintained profitability and are gratified that we were able to recently add new customers who recognize the important value we provide.”
Contact:
HemaCare Corporation
Robert S. Chilton
Executive Vice President and Chief Financial Officer
877-310-0717
www.hemacare.com
Bio-Path Holdings, Inc. Operations Update
Posted on 03. Nov, 2009 by PublicWire in Medical
HOUSTON–(Public Wire)– Bio-Path Holdings, Inc. (OTC BB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, issued a news release today in which the Company provided an update of drug development operations.
Previously in June of 2009, Bio-Path Holdings, Inc. issued a press release in which drug development operations and the status of commencing a Phase I clinical trial in the Company`s lead drug candidate were discussed. In that update, the Company indicated that the next major milestones were successful manufacturing of the clinical drug batch to be used in the Phase I trial, and submission of all drug manufacturing and testing data to the U.S. Food and Drug Administration (FDA). The Company confirms today that its suppliers have successfully manufactured the clinical drug batch, and that all release testing required for this drug has been completed. As a result, Bio-Path Holdings, Inc. in October submitted the necessary drug batch manufacturing and testing data to the FDA. Assuming FDA reviewers have no additional requests for information, the Company expects within 30 days that the Investigational New Drug (IND) application for its lead drug candidate will be released. Bio-Path Holdings, Inc. would then be able to commence its Phase I clinical trial.
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. is developing leading-edge, patented, liposomal drug delivery systems developed at The University of Texas M. D. Anderson Cancer Center, with two clinical cancer drug candidates ready for the clinic, and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path`s drug delivery technology distributes nucleic acid drugs systemically, throughout the human body, via simple intravenous infusion. The delivery technology can be applied both to double stranded (siRNA) and single stranded (antisense) nucleic acid compounds, with the potential to revolutionize the treatment of cancer and other diseases where drugable targets of disease are well characterized.
Bio-Path Holdings, Inc. will also be developing liposome tumor targeting
technology, representing next-generation enhancements to the Company`s core
liposome delivery technology.
Bio-Path Holdings, Inc.
Internal Public Relations:
Douglas P. Morris, VP Corporate Development
801-580-2326
